Understanding how PD-1 signaling affects T cells in cancer treatment
Official title: Detection of PD-1 inhibitory signaling and its molecular relays in T cells: Implications for cancer immunotherapy
Funded at Beth Israel Deaconess Medical Center · NIH-11003708 · Data updated 2026-11-12
This study is looking at how a protein called PD-1 affects T cells, which are important for fighting cancer, and it aims to find ways to boost these cells' ability to work better against tumors in cancer patients.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Beth Israel Deaconess Medical Center NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | January 1, 2023 |
| Project end | December 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $709,419 |
| NIH project number | 5R01CA257672-03 |
| Project ID | NIH-11003708 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients with cancers that are currently treated with PD-1 blocking agents.
✕Less likely to help
Patients with cancers that do not involve PD-1 signaling or those who are not candidates for immunotherapy may not benefit from this research.
What this research studies
This research investigates the role of PD-1 signaling in T cells and how it impacts their ability to fight cancer. By examining the interactions between PD-1 and its ligands in both tumor environments and healthy individuals, the study aims to uncover the mechanisms that inhibit T cell activation. The researchers have developed a specific antibody to detect a phosphorylated form of PD-1, which is crucial for understanding its inhibitory effects. This work could lead to improved strategies for enhancing anti-tumor immunity in cancer patients.
Why it matters
Potential benefit: If successful, this research could lead to more effective cancer immunotherapies that enhance the body's ability to fight tumors.
How similar studies have gone: Previous research has shown promising results with PD-1 blockade in cancer treatment, indicating that this approach has potential for significant advancements.
Where this research is happening
-
Beth Israel Deaconess Medical Center
Boston, United States Active
Researchers
- Principal investigator: Boussiotis, Vassiliki a — Beth Israel Deaconess Medical Center
- Study coordinator: Boussiotis, Vassiliki a
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.